PTGS2 and atherosclerosis: Similarly, some studies show a pro-atherogenic phenotype of COX-2 inhibition [14], [15] or deletion [13], [16], although other pharmacological studies have suggested no change [17], [18], [19], [20] or reduced atherosclerosis [21] with pharmacological blockage of COX-2.